These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 807548)

  • 41. [Comparison of the antibacterial activity of amikacin (BB-K8) with other aminoglycosides against pathogens recently isolated from clinical materials (author's transl) ].
    Kosakai N; Oguri T
    Jpn J Antibiot; 1975 Aug; 28(4):530-7. PubMed ID: 240047
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antibacterial effect and toxicity of synthesized salicylanilide derivatives.
    Ghazi IM; Mohamed ZA; Ismail SA; Kamal A
    Zentralbl Mikrobiol; 1986; 141(3):225-32. PubMed ID: 3094282
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Divergent Synthesis of Three Classes of Antifungal Amphiphilic Kanamycin Derivatives.
    Zhang Q; Alfindee MN; Shrestha JP; Nziko VP; Kawasaki Y; Peng X; Takemoto JY; Chang CT
    J Org Chem; 2016 Nov; 81(22):10651-10663. PubMed ID: 27715046
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemical modification of aminoglycosides. 3. Synthesis of 2"-deoxykanamycins from neamine.
    Reid RJ; Mizsak SA; Reineke LM; Zurenko GE; Stern KF; Magerlein BJ
    J Med Chem; 1981 Dec; 24(12):1487-92. PubMed ID: 7310825
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibacterial activity of the combination ampicillin-kanamycin against gram-negative bacteria.
    Klastersky J; Daneau D; Van Moer N
    Pathol Biol (Paris); 1972 May; 20(9):443-8. PubMed ID: 4625078
    [No Abstract]   [Full Text] [Related]  

  • 46. [Clinical experience with amikacin (BB-K8) (author's transl)].
    Nakagawa K; Watanabe K; Kabe J; Suzuki T; Koyama S
    Jpn J Antibiot; 1974 Jun; 27(3):337-42. PubMed ID: 4215897
    [No Abstract]   [Full Text] [Related]  

  • 47. [Laboratory and clinical studies on amikacin (BB-K8) (author's transl)].
    Kawamori Y; Nishizawa N; Mano D
    Jpn J Antibiot; 1974 Jun; 27(3):348-53. PubMed ID: 4215899
    [No Abstract]   [Full Text] [Related]  

  • 48. [Laboratory and clinical investigation of amikacin (BB-K8) (author's transl)].
    Kato Y; Saito A; Ishikawa K; Nakayama I; Tomizawa M
    Jpn J Antibiot; 1974 Jun; 27(3):343-7. PubMed ID: 4215898
    [No Abstract]   [Full Text] [Related]  

  • 49. Potentiating 1-(2-hydroxypropyl)-2-styryl-5-nitroimidazole derivatives against antibacterial agents: design, synthesis and biology analysis.
    Wang ZC; Duan YT; Qin YJ; Wang PF; Luo Y; Wen Q; Yang YA; Sun J; Hu Y; Sang YL; Zhu HL
    Eur J Med Chem; 2013 Jul; 65():456-63. PubMed ID: 23770447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Naphthyridinomycin, a new broad-spectrum antibiotic.
    Kluepfel D; Baker HA; Piattoni G; Sehgal SN; Sidorowicz A; Singh K; Vézina C
    J Antibiot (Tokyo); 1975 Jul; 28(7):497-502. PubMed ID: 807549
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Design, synthesis, and antibacterial activities of conformationally constrained kanamycin A derivatives.
    Zhang W; Chen Y; Liang Q; Li H; Jin H; Zhang L; Meng X; Li Z
    J Org Chem; 2013 Jan; 78(2):400-9. PubMed ID: 23228010
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inhibition of growth and uptake processes in bacteria by some chemical food preservatives.
    Eklund T
    J Appl Bacteriol; 1980 Jun; 48(3):423-32. PubMed ID: 6773919
    [No Abstract]   [Full Text] [Related]  

  • 53. Cefoxitin: synergism with aminoglycosides in vitro.
    Une T; Osada Y; Ogawa H
    Arzneimittelforschung; 1981; 31(5):761-4. PubMed ID: 6791664
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EM49, a new peptide antibiotic. I. Fermentation, isolation, and preliminary characterization.
    Meyers E; Brown WE; Principe PA; Rathnum ML; Parker WL
    J Antibiot (Tokyo); 1973 Aug; 26(8):444-8. PubMed ID: 4209531
    [No Abstract]   [Full Text] [Related]  

  • 55. [Antimicrobial activity against E. coli and Pseudomonas of lividomycin].
    Goto Y; Onuma M
    Jpn J Antibiot; 1972 Dec; 25(6):340-2. PubMed ID: 4198942
    [No Abstract]   [Full Text] [Related]  

  • 56. Tolypomycin, a new antibiotic. 3. Isolation and characterization of tolypomycin Y.
    Kishi T; Yamana H; Muroi M; Harada S; Asai M
    J Antibiot (Tokyo); 1972 Jan; 25(1):11-5. PubMed ID: 4622052
    [No Abstract]   [Full Text] [Related]  

  • 57. [Relations between chemical constitution and antimicrobial effect in beta-aminoketones. 8. Cytostatics].
    Schönenberger H; Bastug T; Adam D
    Arzneimittelforschung; 1969 Jul; 19(7):1082-91. PubMed ID: 4981207
    [No Abstract]   [Full Text] [Related]  

  • 58. Synthesis, antibacterial activities and molecular docking studies of Schiff bases derived from N-(2/4-benzaldehyde-amino) phenyl-N'-phenyl-thiourea.
    Zhang HJ; Qin X; Liu K; Zhu DD; Wang XM; Zhu HL
    Bioorg Med Chem; 2011 Sep; 19(18):5708-15. PubMed ID: 21872479
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Synthesis and biological activity of 1-N-[4-(substituted)amidino and guanidino-2-hydroxybutyryl]kanamycins A and B.
    Yamasaki T; Narita Y; Hoshi H; Aburaki S; Kamei H; Naito T; Kawaguchi H
    J Antibiot (Tokyo); 1991 Jun; 44(6):646-58. PubMed ID: 2071490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of resistance to kanamycin.
    Griffith LJ
    Ann N Y Acad Sci; 1966 Jun; 132(2):796-9. PubMed ID: 4960372
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.